Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Immuneering Corporation (IMRX) PT Lowered to $1.50 at Jefferies
May 8, 2024 7:39 AM EDTJefferies analyst Michael Yee lowered the price target on Immuneering Corporation (NASDAQ: IMRX) to $1.50 (from $3.00) while maintaining a Hold rating.
The analyst comments "IMRX reported the Q with no surprises and reiterated key timelines for two data readouts coming in H2:... More
